tb-500 mastery course
Unit 10 of 12
safety & risk profile
side effects, cancer risk, contraindications, and quality control
What We Know and Don't Know
Ruff 2010 tolerated IV TB4 up to 1,260 mg over 14 days, which says nothing about the chronic subcutaneous dosing the community uses.
A peptide that drives angiogenesis and cell migration could, in theory, help tumors grow. TB4 is overexpressed in colorectal, pancreatic, and NSCLC tumors. Whether that means real risk at community doses is untested.
1
phase I human safety trial (Ruff 2010)
14 d
longest dosing window in humans
3+
tumor types with TB4 overexpression
0
long-term outcome studies
The gap is uncertainty, not proof of harm. Anyone with active cancer or strong family history should stay off.
what evidence actually exists for TB-500 safety
click each tier for what the data shows.
tb-500 safety evidence hierarchy
The Cancer Question: Theoretical vs Tested
known vs assumed.
cancer risk evidence framework
Interactive Safety Matrix
risk categories and evidence levels.
safety risk matrix